Saturday 17 October 2026
Export MBRX’s income statement to Excel — free account
Moleculin Biotech, Inc.
MBRX Healthcare Biotechnology
In the quarter to June 2026, EPS grew 95.1% and free cash flow fell 19.3%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.28
0.09
−24.32%
Follow MBRX
Moleculin Biotech, Inc. (MBRX) P/E ratio
As of 16 October 2026, Moleculin Biotech, Inc. (MBRX) trades at a P/E ratio of 0.0×. Over the past ten years it has ranged from 0.0× (June 2026) to 0.2× (June 2026); the current reading is higher than 97% of that period. That is below the Biotechnology industry median of 8.5× and below the Healthcare sector median of 23.0×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.2×
Ten-year median
0.0×
Current reading's percentile
97
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| KPTI Karyopharm Therapeutics Inc. compare | n/m |
| APRE Aprea Therapeutics, Inc. compare | n/m |
| CNSP CNS Pharmaceuticals, Inc. compare | n/m |
| XCUR Exicure, Inc. compare | n/m |
| SNGX Soligenix Inc. compare | n/m |
| SKYE Skye Bioscience, Inc. compare | n/m |
| CALC CalciMedica Inc. compare | n/m |
| CURX Curanex Pharmaceuticals Inc compare | n/m |
| MBRX Moleculin Biotech, Inc. | 0.0× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)